NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US) Committee on Xenograft Transplantation: Ethical Issues and Public Policy. Xenotransplantation: Science, Ethics, and Public Policy. Washington (DC): National Academies Press (US); 1996.

Cover of Xenotransplantation

Xenotransplantation: Science, Ethics, and Public Policy.

Show details

References

  1. Allan JS.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995a.
  2. Allan JS. Xenograft transplantation and the infectious disease conundrum. ILAR J. 1995b;37(1):37–48. [PubMed: 11528023]
  3. American Medical Association (AMA); Council on Ethical and Judicial Affairs. The use of anencephalic neonates as organ donors. JAMA. 1995;273:1614–1618. [PubMed: 7745776]
  4. Arnold R.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  5. Bach Fritz H, Robson Simon C, Ferran Christiane, Winkler Hans, Millan Maria T, Tuhlmeier Karl M, Bernard Vanhove, Blakely Martin L, Van der Werf William J, Erhard Hofer, Martin Rainer de, Hancock Wayne M. Endothelial cell activation and thromboregulation during xenograft rejection. Immunol. Rev. 1994;141:5–30. [PubMed: 7868157]
  6. Bach Fritz H, Robson Simon C, Winkler Hans, Ferran Christiane, Stuhlmeier Karl, Wrighton Christopher, Hancock Wayne W. Barriers to xenotransplantation. Nature Med. 1995;1:869–873. [PubMed: 7585204]
  7. Bach FH, Turman MA, Vercellotti GM, Platt JL, Dalmasso AP. Accommodation: A working paradigm for progressing toward discordant xenografting. Transplant. Proc. 1991;23:205–208. [PubMed: 1990513]
  8. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 1984;160:618–623. [PMC free article: PMC2187463] [PubMed: 6332168]
  9. Bowman JE.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  10. Caplan AL. Is xenografting morally wrong? Transplant. Proc. 1992;24(2):722–727. [PubMed: 1566500]
  11. Chapman LE.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  12. Chapman LE, Folks TM, Salomon DR, Patterson AP, Eggerman TE, Noguchi PD. Xenotransplantation and xenogeneic infections. N. Engl. J. Med. 1995;333(22):1498–1501. [PubMed: 7477153]
  13. Cooper DKC.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  14. Cooper DKC, Koren E, Oriol R. Oligosaccharides and discordant xenotransplantation. Immunol. Rev. 1994;141:31–58. [PubMed: 7868156]
  15. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation. 1991;52:530–533. [PubMed: 1716798]
  16. Dresser R.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1985 June 25-27; 1995.
  17. Evans RW. Money matters: Should ability to pay ever be a consideration in gaining access to transplantation? Transplant. Proc. 1989;21:3419–3423. [PubMed: 2662485]
  18. Evans RW., UCLA Tissue Typing Laboratory. Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit. In: Terasaki PI, Cecka JM, editors. Clinical Transplantation. Los Angeles: UCLA School of Medicine; 1993. pp. 359–391. [PubMed: 7918169]
  19. Evans RW. Liver transplantation in a managed care environment. Liver Trans. Surg. 1995a;1:61–75. [PubMed: 9346544]
  20. Evans RW.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995b.
  21. Evans RW, Blagg CR, Bryan F. Implications for health care policy: A social and demographic profile of hemodialysis patients in the U.S. JAMA. 1981;245:487–491. [PubMed: 6779018]
  22. Faustman D. 1995Strategy for successful xenograft survival: Designer modification of cells, tissues and organs. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy 1995 June 25-27.
  23. Faustman D, Coe C. Prevention of xenograft rejection by masking donor HLA class 1 antigens. Science. 1991;252:1700–1702. [PubMed: 1710828]
  24. Fodor WL, Williams BL, Matis LA. et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl. Acad. Sci. USA. 91:11153–11157. [PMC free article: PMC45185] [PubMed: 7526391]
  25. Fox RC.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  26. Fox RC, Swazey JP. New York: Oxford University Press; 1992. Spare Parts: Organ Replacement in American Society.
  27. Gaines BA, Ildstad ST. Xenoreactivity, chimerism, and tolerance. In: Ildstad ST, editor. Chimerism and Tolerance. R.G. Lanes Company Publishers; 1995. pp. 172–188.
  28. Gianelli DM. Ethics council reverses stand on anencephalic organ donors. Am. Med. News. 1995;38(48):3–8.
  29. Hammer C. Evolutionary considerations in xenotransplantation. In: Hardy MA, editor. Xenograft. Vol. 25. 1989. pp. 115–123. (Congress Series 880.).
  30. Hancock WW. Analysis of intragraft effector mechanisms associated with human renal allograft rejection: Immunohistological studies using monoclonal antibodies. Immunol. Rev. 1984;77:61–84. [PubMed: 6232203]
  31. Ildstad S.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  32. Institute of Medicine (IOM). Washington, DC: National Academy Press; 1991. Kidney Failure and the Federal Government.
  33. Institute of Medicine (IOM). Washington DC: National Academy Press; 1992. Emerging Infections: Microbial Threats to Health in the United States.
  34. Kahan BD.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  35. Kahan BD, R Ghobrial. Immunosuppressive agents. Surg. Clin. North Am. 1994;74:1029–1054. [PubMed: 7940060]
  36. Kaufman CL, YL Colson, SM Wren. et al. Phenotypic characterizations of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84(8):2436–2445. [PubMed: 7919363]
  37. Kaufman C, Gaines Barbara A, Ildstad Suzanne T. Xenotransplantation. Ann. Rev. Immunol. 1995;13:339–367. [PubMed: 7612227]
  38. Keeling M.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  39. Kessler DA, Siegel JP, Noguchi PD. et al. Regulation of somatic cell therapy and gene therapy by the Food and Drug Administration. N. Engl. J. Med. 1993;329:1169–1173. [PubMed: 8377782]
  40. Khabbaz RF, Heneine W, George JR. et al. Brief report: Infection of a laboratory worker with simian immunodeficiency virus. N. Engl. J. Med. 1994;330:172–177. [PubMed: 8264739]
  41. Koller B.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  42. McCarthy CR. Ethical aspects of animal to human xenografts. ILAR J. 1995;37(1):3–8. [PubMed: 11528017]
  43. McKenzie JFC, Cohney S, Vaughan HA, Osman N, Atkin J, Elliott E, Fodor WL, Gallop MA, Oldenburg KR, Burton D, Sandrin MS. Overcoming the anti-Gala(1-3)Gal reaction in xenotransplantation. Xenotransplantation. 1995;3:86–89.
  44. Menzel PT. Some ethical costs of rationing. In: Mattheiu D, editor. Organ Substitution Technology. Boulder, CO: Westview Press; 1988. pp. 155–164.
  45. Menzel PT. Scarce dollars for saving lives: The case of heart and liver transplants. Law, Med., and Health Care. 1992;20:57–66. [PubMed: 1630143]
  46. Menzel PT.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  47. Merrill RA.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  48. Michaels M.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  49. Michaels MG, RL Simmons. Xenotransplant-associated zoonoses. Strategies for Prevention. Transplantation. 1994;57:1–7. [PubMed: 8291094]
  50. Morse S.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  51. Moskop JC. Ability to pay and access to transplantation. In: Land W, Dossetor JG, editors. Organ Replacement Therapy: Ethics, Justice, Commerce. Berlin: Springer-Verlag; 1991. pp. 433–436.
  52. National Research Council. Washington, DC: National Academy Press; 1989. Improving Risk Perception and Communication.
  53. Persing D.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  54. Platt JL. A perspective on xenograft rejection and accommodation. In: Moller G, editor. Immunological Reviews. Vol. 141. 1994. pp. 127–149. [PubMed: 7868152]
  55. Platt JL.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  56. Platt JL, Vercellotti GM, B Lindman, Oegema TR Jr, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells: Implications for pathogenesis of hyperacute rejection. J. Exp. Med. 1990;171:1363–368. [PMC free article: PMC2187844] [PubMed: 2139104]
  57. Pober JS, Gimbrone MA Jr. Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: Demonstration by monoclonal antibody binding and immunoprecipitation. Proc. Natl. Acad. Sci. USA. 1982;53:1851–1854. [PMC free article: PMC347184] [PubMed: 6815654]
  58. Ricordi C.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  59. Rothman D.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  60. Scharp D, Swanson CJ, Olack BJ. et al. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes. 1994;43:1167–1170. [PubMed: 8070618]
  61. Siminoff L, Arnold RM, Caplan AL, Virnig BA, Seltzer DL. Public policy governing organ and tissue procurement in the United States. Ann. Intern. Med. 1995;123:10–17. [PubMed: 7762908]
  62. Spital A. Mandated choice: A plan to increase public commitment to organ donation. JAMA. 1995;273(6):504–506. [PubMed: 7837372]
  63. Squinto S, Fodor WL.Transgenic swine engineered to be resistant to the humoral immune system of primates; Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  64. Starzl TE.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  65. Starzl TE, Demetris AJ, Trucco M. et al. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology. 1993;17(6):1127–1152. [PMC free article: PMC2964270] [PubMed: 8514264]
  66. Swindle M.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
  67. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N. Engl. J. Med. 1995;333(6):333–336. [PubMed: 7609748]
  68. United Network for Organ Sharing (UNOS). Richmond, VA: UNOS; Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network--Transplant Data: 1988-1994. 1994
  69. U.S. Bureau of Labor Statistics (BLS). Employee Benefits in Medium and Large Private Establishments, 1993. Washington, D.C.: U.S. Department of Labor; Bulletin 2456. 1994
  70. U.S. Food and Drug Administration (FDA). Application of current statutory authorities to human somatic cell therapy products and gene therapy products. Federal Register Notice. Oct 14, 1993.
  71. Walters J.Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy; 1995 June 25-27; 1995.
Copyright © 1996, National Academy of Sciences.
Bookshelf ID: NBK45529

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...